echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Cancer breakthrough: Predict within hours whether a cancer patient will survive chemotherapy

    Cancer breakthrough: Predict within hours whether a cancer patient will survive chemotherapy

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
          

       

    Benedicte Sjo Tislevoll


    Researchers at the University of Bergen in Norway have discovered a new method that can predict within hours whether certain cancer patients will survive
    chemotherapy.

    Acute myeloid leukemia is an aggressive blood cancer with a low
    survival rate.
    Although the initial chemotherapy response rate is high, patients often relapse
    due to the selection and development of chemotherapy-resistant leukemia cells.

    Benedicte Sjo Tislevoll, a researcher at the University of Bergen and leader of the new study, said: "When treating people with leukemia, it is a challenge
    to fast-track whether a patient is responding to treatment.
    "

    Current response to treatment is measured weeks to months after treatment, thus wasting significant time
    .
    However, the immediate response to chemotherapy can be measured
    by studying the functional properties of leukemia cells.

    "Our findings show that ERK1/2 protein increases
    in the first 24 hours of chemotherapy in patients who respond poorly to treatment.
    We believe that this protein is responsible for cancer cells' resistance to chemotherapy and can be used to distinguish between responders and non-responders
    .

    Tislevoll concluded: "We think this is an important key to our understanding of cancer, and our goal is to use this information to change treatments early on to patients who do not respond to treatment
    .
    "

    Early response evaluation by single cell signaling profiling in acute myeloid leukemia
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.